A seed investment of €8.5 million was obtained by Captain T Cell, a biotechnology business situated in Schoenefeld/Berlin, Germany, that develops T cells to combat solid tumors.
Investors
- i&i Biotech Fund I SCSp
- HIL-INVENT Ges.m.b.H.
- Brandenburg Kapital GmbH
- the German Federal Ministry of Education and Research (BMBF) under the GO-Bio initiative
- Along with the funding, Jörn Aldag is now the Chairman of the Board of Directors.
Use of funds
The funding will be used by the business to advance its lead program into clinical trials and to develop a revolutionary allogeneic platform for off-the-shelf solid tumor therapies.
The business is a spin-off of the renowned European center for biomedical research, the Max Delbrück Center in Berlin, Germany.
About Captain T Cell
Under the direction of CEO Dr. Felix Lorenz, Captain T Cell creates TCR-T cells with improved effectiveness for solid cancers that are unresponsive to current treatments. It produces TCR-T cells with increased persistence and the ability to survive in the unfriendly tumor microenvironment of solid tumors that are challenging to treat by using a toolkit of technologies. The business has used these efficaciously-enhanced T cells to remove aggressive malignancies in preclinical in vivo models. The exclusive TCR-ALLO platform, developed by the Captain T Cell team, is a crucial technology for the off-the-shelf treatment of solid tumors. It is an adaptable instrument that can be extended to a range of cancer indications.
